CN116172191A - Nutritional composition and its application in preparing anti-inflammatory products - Google Patents
Nutritional composition and its application in preparing anti-inflammatory products Download PDFInfo
- Publication number
- CN116172191A CN116172191A CN202310273135.4A CN202310273135A CN116172191A CN 116172191 A CN116172191 A CN 116172191A CN 202310273135 A CN202310273135 A CN 202310273135A CN 116172191 A CN116172191 A CN 116172191A
- Authority
- CN
- China
- Prior art keywords
- calcium
- content
- weight
- parts
- lactoferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 18
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 67
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 67
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 67
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 67
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 67
- 102000004264 Osteopontin Human genes 0.000 claims abstract description 62
- 108010081689 Osteopontin Proteins 0.000 claims abstract description 62
- 239000011575 calcium Substances 0.000 claims abstract description 50
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 50
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 235000018102 proteins Nutrition 0.000 claims abstract description 26
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 19
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 13
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 60
- 229960005069 calcium Drugs 0.000 claims description 48
- 235000015097 nutrients Nutrition 0.000 claims description 40
- 235000001465 calcium Nutrition 0.000 claims description 38
- 239000011707 mineral Substances 0.000 claims description 34
- 235000010755 mineral Nutrition 0.000 claims description 34
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 23
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 235000013336 milk Nutrition 0.000 claims description 20
- 239000008267 milk Substances 0.000 claims description 20
- 210000004080 milk Anatomy 0.000 claims description 20
- 235000014633 carbohydrates Nutrition 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 17
- 229930003231 vitamin Natural products 0.000 claims description 17
- 235000013343 vitamin Nutrition 0.000 claims description 17
- 239000011782 vitamin Substances 0.000 claims description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 16
- 108010076119 Caseins Proteins 0.000 claims description 16
- 102000011632 Caseins Human genes 0.000 claims description 16
- 239000001110 calcium chloride Substances 0.000 claims description 16
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 16
- 229960002713 calcium chloride Drugs 0.000 claims description 16
- 235000011148 calcium chloride Nutrition 0.000 claims description 16
- 102000007544 Whey Proteins Human genes 0.000 claims description 13
- 108010046377 Whey Proteins Proteins 0.000 claims description 13
- 229920002774 Maltodextrin Polymers 0.000 claims description 12
- 239000005913 Maltodextrin Substances 0.000 claims description 12
- 239000003925 fat Substances 0.000 claims description 12
- 235000019197 fats Nutrition 0.000 claims description 12
- 229940035034 maltodextrin Drugs 0.000 claims description 12
- 235000021119 whey protein Nutrition 0.000 claims description 11
- 239000005018 casein Substances 0.000 claims description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 9
- 235000021240 caseins Nutrition 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 7
- 239000002285 corn oil Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 229940080237 sodium caseinate Drugs 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000020238 sunflower seed Nutrition 0.000 claims description 5
- 108010033929 calcium caseinate Proteins 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 235000020248 camel milk Nutrition 0.000 claims description 4
- 235000020247 cow milk Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 235000020254 sheep milk Nutrition 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229960003563 calcium carbonate Drugs 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- XHJPNDHCQYJODA-MUWMCQJSSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;calcium Chemical compound [Ca].C[C@@H](O)[C@H](N)C(O)=O XHJPNDHCQYJODA-MUWMCQJSSA-N 0.000 claims description 2
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000014171 Milk Proteins Human genes 0.000 claims description 2
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- 229940034055 calcium aspartate Drugs 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000021243 milk fat Nutrition 0.000 claims description 2
- 108010071421 milk fat globule Proteins 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 235000013350 formula milk Nutrition 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 16
- 230000035764 nutrition Effects 0.000 description 16
- 102100040557 Osteopontin Human genes 0.000 description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 14
- -1 sensitivity Diseases 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000008101 lactose Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 229940090949 docosahexaenoic acid Drugs 0.000 description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 7
- 235000021342 arachidonic acid Nutrition 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 5
- 235000019743 Choline chloride Nutrition 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 5
- 229960003178 choline chloride Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical group OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 208000012876 acute enteritis Diseases 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000190079 Turnera Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OFNJDDJDXNMTHZ-UHFFFAOYSA-L calcium;2-aminoacetate Chemical compound [Ca+2].NCC([O-])=O.NCC([O-])=O OFNJDDJDXNMTHZ-UHFFFAOYSA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical group 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides nutritional compositions and their use in the preparation of anti-inflammatory products. The present invention provides the use of a nutritional composition in the preparation of an anti-inflammatory product; the nutritional composition comprises protein, fat, carbohydrate and calcium salt; the proteins include lactoferrin and osteopontin; in the nutritional composition, the total protein content is (9-50 g)/100 g, the fat content is (12-30 g)/100 g, the carbohydrate content is (30-60 g)/100 g, the lactoferrin content is (0.005-3 g)/100 g, the osteopontin content is (0.01-1 g)/100 g, and the calcium content is (0.1-2 g)/100 g. The nutritional composition contains lactoferrin, osteopontin and calcium, has a synergistic inhibition effect on chronic inflammation which is easy to generate for tumor patients, wound stress patients and the like, has high safety, and is worthy of popularization and application.
Description
Technical Field
The present invention relates to the field of food technology, and more specifically to nutritional compositions and their use in the preparation of anti-inflammatory products.
Background
Tumors are the most common disease which endangers life and health of people at present, and the mortality rate is the first. Along with the continuous development of medical technology, the tumor treatment technology is also continuously improved and promoted, more and more tumor patients are improved in disease condition, but the number of recurrence and metastasis cases is still more, and related medical staff are required to attach importance to rehabilitation and health care of the tumor patients. Several epidemiological studies have shown that more than 2/3 of tumor patients can be prevented by taking appropriate lifestyles. It was found that a lactoferrin enriched diet can act as a prophylactic. Osteopontin is an important component of the extracellular matrix of tumors and is considered a key marker for the progression of many tumors.
Patients with post-traumatic stress disorder may develop emotional symptoms, including increased alertness, sensitivity, irritability to the environment, avoidance and numbness to daily life, or become turnera. Surgical trauma stress can induce a peripheral inflammatory response in the body, which destroys the integrity of the blood brain barrier by inflammatory cells, pro-inflammatory factors, or activates a series of neural and humoral mechanisms such as vagal primary neurons by transport proteins, related receptors, or by immune related stimulation, thereby activating microglial cells, producing a series of inflammatory mediators leading to an inflammatory response in the central nervous system, and eventually damaging the hippocampal brain region leading to PND. In the implementation of nutritional support for trauma patients, it is important to provide sufficient and appropriate proportions of heat to the patient, and the heat balance is closely related to mortality in critically ill patients, and damage to the intestinal mucosal barrier can occur early in the trauma.
Lactoferrin is involved in a wide range of biological functions including anti-infective, anti-inflammatory and reducing the detrimental host response to acute enteritis. Among them, lactoferrin plays an important immunological role as a key immunonutrient in breast milk. In piglets fed lactoferrin, immune cells produce a strong pro-inflammatory response when the bacteria trigger. These studies demonstrate the benefits of dietary lactoferrin in preventing infection, late sepsis and necrotizing enterocolitis.
The osteopontin is a multifunctional protein with biological activity, exists in most tissues and body fluids, and is found to be capable of remarkably promoting human small intestine gland fossa cell proliferation, reducing the activity of intestinal neutrophil in acute enteritis mice, reducing the secretion of a series of pro-inflammatory factors such as tumor necrosis factor (TNF-alpha), interferon gamma and the like, and reducing harmful host reactions by enhancing and restoring epithelial barriers and the like.
In the prior art, the anti-inflammatory effect of the calcium ion, lactoferrin and osteopontin, which is easily generated in adult disease states of tumor patients, trauma stress patients and the like, is not clear, and needs to be further explored.
Disclosure of Invention
In view of the above, the present invention aims to provide a nutritional composition and an application thereof in preparing anti-inflammatory products, wherein the nutritional composition contains lactoferrin, osteopontin and calcium, has a synergistic inhibition effect on chronic inflammation which is easy to occur in adult diseased states of tumor patients, trauma stress patients and the like, has high safety, and is worthy of popularization and application.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
use of a nutritional composition for the preparation of an anti-inflammatory product;
the nutritional composition comprises protein, fat, carbohydrate and calcium salt;
the proteins include lactoferrin and osteopontin;
in the nutritional composition, the total protein content is (9-50 g)/100 g, the fat content is (12-30 g)/100 g, the carbohydrate content is (30-60 g)/100 g, the lactoferrin content is (0.005-3 g)/100 g, the osteopontin content is (0.01-1 g)/100 g, and the calcium content is (0.1-2 g)/100 g.
In the invention, the mass ratio of the lactoferrin to the osteopontin to the calcium is 1 (0.1-5) (0.001-40); the mass ratio of the lactoferrin to the osteopontin to the calcium is preferably 1 (0.1-5): (0.011 to 0.06), more preferably 1: (0.1-5): (0.011-0.02).
In the present invention, the anti-inflammatory includes inhibiting the expression of a pro-inflammatory factor-related gene, and/or down-regulating the expression of an inflammatory pathway-related protein;
the pro-inflammatory factors include IL-1β and/or IL-6, preferably IL-1β;
the inflammatory pathway related proteins include one or more of TLR4, p-p65, p-STAT 3.
In the present invention, the anti-inflammatory product is preferably a food product;
the anti-inflammatory product is a formula food with special medical application; special medical use formulas, which are formulas specially processed and formulated to meet the special needs of people with limited eating, digestive absorption disorder, metabolic disorder or specific disease states for nutrients or diet, include special medical use infant formulas applicable to 0 to 12 months of age and special medical use formulas applicable to people over 1 year of age;
the anti-inflammatory is preferably against chronic inflammation;
the patient producing the chronic inflammation is preferably a tumor patient or a trauma stress patient. Chronic inflammation (chronic inflammation) is a long-term, slowly progressing inflammation that can last for several months to years, and sometimes is not known by itself under the duration of chronic inflammation. Chronic inflammation and related diseases are the leading causes of death in humans. Stress can cause chronic systemic low-grade inflammation of organisms, wherein the chronic low-grade inflammation is soil with various diseases, and further has negative effects on human health; tumor development and progression are associated with chronic inflammation. The microenvironment consisting of chronic inflammation is critical for the occurrence, development and metastasis of tumors, and is also the response of the body to tumors, and in general, the inflammation has a promoting effect on the tumors.
In the nutritional composition of the present invention, the total protein content is (15-35 g)/100 g, the fat content is (12-20 g)/100 g, the carbohydrate content is (32-50 g)/100 g, the lactoferrin content is (0.005-0.8 g)/100 g, the osteopontin content is (0.03-0.5 g)/100 g, and the calcium content is (0.1-1 g)/100 g.
For one embodiment of the invention, the nutritional composition has a total protein content of 34g/100g, a fat content of 12g/100g, a carbohydrate content of 32g/100g, a lactoferrin content of 600mg/100g, a osteopontin content of 60mg/100g, and a calcium content of 300mg/100g.
For one embodiment of the invention, the nutritional composition has a total protein content of 33g/100g, a fat content of 18.5g/100g, a carbohydrate content of 34g/100g, a lactoferrin content of 16mg/100g, a osteopontin content of 80mg/100g, and a calcium content of 640mg/100g.
In the present invention, the lactoferrin is derived from one or more of cow milk or a product thereof, sheep milk or a product thereof, camel milk or a product thereof, preferably whey protein powder.
In the present invention, the osteopontin is derived from one or more of cow milk or a product thereof, sheep milk or a product thereof, camel milk or a product thereof, preferably whey protein powder.
In the present invention, the calcium salt is derived from one or more of calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, calcium hydrogen phosphate, calcium L-threonine, calcium glycinate, calcium aspartate, calcium acetate, calcium chloride, tricalcium phosphate, vitamin E calcium succinate, calcium glycerophosphate, calcium sulfate, calcium dihydrogen phosphate, milk mineral salts, calcium caseinate, calcium malate, and calcium ascorbate. Milk mineral salt is also called milk calcium, whey mineral concentrate and whey calcium, and is milk white powder obtained by processing milk through membrane permeation, separation, concentration, spray drying and other processes, and the main component of the milk mineral salt is calcium phosphate, and the milk mineral salt also comprises rich nutritional components such as protein, lactose, zinc, phosphorus, sodium, potassium, magnesium and the like, wherein the calcium content is about 23% -28%, the calcium-phosphorus ratio is 2:1, and the milk mineral salt is more beneficial to absorption and utilization of human bodies.
In the invention, the raw materials for providing the protein comprise one or more of sodium caseinate, calcium caseinate, casein, hydrolyzed whey protein, hydrolyzed casein, hydrolyzed milk protein, hydrolyzed milk fat globule membrane protein and separated whey protein;
the raw materials for providing the fat comprise one or more of milk fat, vegetable oil, fish oil and triglyceride; the triglycerides are preferably medium chain triglycerides;
the vegetable oil is one or more selected from sunflower seed oil, corn oil, coconut oil, canola oil, linseed oil, peanut oil, soybean oil, palm oil and walnut oil; preferably sunflower seed oil, corn oil and soybean oil; the addition of vegetable oil provides on the one hand a fat component for the nutritional composition and on the other hand linoleic acid and also alpha-linolenic acid; more preferably, the raw material thereof contains 0 to 150 parts by weight of sunflower seed oil based on 1000 parts by weight of the nutritional composition; corn oil 0-80 weight portions; 0-80 parts by weight of soybean oil; the addition of fish oil can not only provide a fat component, but also unsaturated fatty acids; unsaturated fatty acids include docosahexaenoic acid (DHA), arachidonic acid (ARA), and eicosapentaenoic acid (EPA);
providing the carbohydrate as a raw material comprising one or more of lactose, gelatinized starch, maltodextrin, solid corn syrup, glucose syrup, and dietary fiber; the carbohydrates in the nutritional compositions of the present invention are derived in part from lactose and in part from non-lactose sources including, but not limited to, gelatinized starch, maltodextrin, solid corn syrup, glucose syrup; that is, in the nutritional composition of the present invention, the carbohydrate-providing raw material includes raw material lactose and starch-based material pre-hydrolyzed and gelatinized in addition to the lactose-containing base raw material; preferably, the nutritional composition comprises, based on 1000 parts by weight, the following raw materials: lactose 0-580 weight portions and non-lactose material 0-580 weight portions; the specific addition amount of lactose of the above raw materials may be adjusted within the range so that the carbohydrate content in the nutritional composition of the present invention is 50 to 58g/100g; the dietary fiber is preferably fructooligosaccharides; fructo-oligosaccharides (FOS) are a natural active substance with sweetness 0.3-0.6 times that of sucrose. The fructo-oligosaccharide not only maintains the pure sweet property of the sucrose, but also is more refreshing than the sweet taste of the sucrose. Has health promoting effects such as regulating intestinal flora, proliferating Bacillus bifidus, promoting calcium absorption, regulating blood lipid, regulating immunity, and resisting dental caries;
the nutritional composition further comprises one or more of amino acids, vitamins;
the amino acids include arginine and/or tryptophan;
in one embodiment of the present invention, the nutritional composition comprises the following raw materials based on 1000 parts by weight: 8-50 parts by weight of DHA and 14-28 parts by weight of ARA; EPA is 10-140 parts by weight; arginine is 0 to 10 weight parts; tryptophan is 0 to 10 weight portions; 0 to 7.5 parts by weight of lactoferrin; 0-75 parts by weight of osteopontin; 7-50 parts by weight of compound nutrient bag containing calcium powder, vitamins and minerals.
In the nutritional composition, the compound nutrient package is a combination of nutritional ingredients meeting the national standard, and different addition amounts are used according to different formulas. The nutritional composition of the invention can optionally adopt any one or any combination of the following compound nutritional package components if nutrients are added according to needs. Preferably, the compound nutrient package at least comprises compound vitamin, calcium powder and mineral nutrient packages, and the content of each component in the compound nutrient package is as follows:
1) A compound vitamin nutrition package, wherein each gram of compound vitamin nutrition package comprises:
taurine: 140-340 mg
Vitamin a: 1700-5800 mu gRE
Vitamin D: 25-70 mu g
Vitamin B 1 ：2000～6800μg
Vitamin B 2 ：3000～6900μg
Vitamin B 6 ：1700～4000μg
Vitamin B 12 ：8～20μg
Vitamin K 1 ：200～700μg
Vitamin C: 0-700 mg
Vitamin E: 10-70 mg alpha-TE
Nicotinamide: 10000-41550 mug
Folic acid: 350-920 mu g
Biotin: 70-245 mug
Pantothenic acid: 7100-25230 mu g
Inositol: 0-250mg
L-carnitine: 0-60mg
2) Mineral one nutrition package, in every gram of mineral one nutrition package:
iron: 20-110 mg
Zinc: 23-90 mg
Copper: 2000-4180 mug
Iodine: 500-995 mug
Selenium: 0-200 mu g
Manganese: 0-579 mug
3) Mineral two nutrition package, in every gram mineral two nutrition package:
sodium: 40-100 mg
Potassium: 200-500 mg
4) Mineral triad package, per gram of mineral triad package:
calcium: 200-500 mg
Phosphorus: 75-300 mg
5) A compound magnesium chloride nutrition package, wherein each gram of compound magnesium chloride nutrition package comprises:
magnesium: 80-170 mg
6) Choline chloride nutrition packet, per gram of choline chloride nutrition packet:
choline: 300-950 mg
The base material of the compound nutrient packet is preferably lactose, maltodextrin, solid corn syrup or L-sodium ascorbate. Based on 1000 parts by weight of the nutritional composition, the addition amount of the compound nutrient package is 7-52 parts by weight, wherein the compound vitamin nutrient package is preferably 2-4 parts by weight, the mineral secondary nutrient package is preferably 2-20 parts by weight, the mineral tertiary nutrient package is preferably 0.5-20 parts by weight, the mineral primary nutrient package is preferably 0.5-6 parts by weight, the magnesium chloride is 0-7 parts by weight, the choline chloride is 0-3 parts by weight, and the base material of each nutrient package is preferably maltodextrin, lactose or sodium L-ascorbate.
The compound materials used to provide each nutrient in the nutritional package may have interactions. For example, sulfate can accelerate the oxidative destruction process of vitamins, which can reduce their utilization. Because sulfate occurs in ionic form in aqueous solution, it acts as an oxidizing agent to induce oxidation of vitamins during the oxidation reaction, thereby destroying the vitamin structure. The trace elements have different capacities in oxidation-reduction reaction, and the activities of copper, zinc and iron are strongest, and manganese and selenium are used for times. Vitamin B and vitamin C are susceptible to copper ions, vitamin B 2 Is susceptible to iron ions.
To ensure nutrient utilization efficiency, the present invention selects stable nutrient dosage forms, such as: the retinol is selected from retinol acetate, and retinol contains 1 hydroxyl group and 5 double bonds, so that the retinol is very easy to oxidize, but the stability of the retinol is greatly improved under the form of the retinol acetate; vitamin E is selected from tocopheryl acetate, the tocopherols are unstable, but the stability of tocopheryl acetate is higher; vitamin B 1 Selecting thiamine nitrate, wherein the thiamine nitrate is more stable than thiamine hydrochloride; the vitamin C is L-sodium ascorbate.
The above-mentioned compound nutrient package component contents refer to the nutrient component contents in other raw materials of the nutrient composition excluding the additive amount for enhancing the nutrient substances, and according to a preferred embodiment of the present invention, the formula of the nutrient composition of the present invention includes:
it will be appreciated that the specific amounts of the ingredients in the nutritional compositions of the present invention should be determined by adjusting the amounts of the ingredients to meet the product specifications of the nutritional composition.
In the nutritional composition of the invention, the raw materials are commercially available, and the raw materials are selected to meet the requirements of relevant standards, wherein the lactoferrin, the osteopontin and the calcium salt meet the requirements of the invention. In addition, the compound nutrient package can also be self-compounded. The invention adopts 'compound' for convenience of expression, and does not mean that all components in the compound are mixed together and then applied. All raw materials should be added and used on the premise of meeting related regulations.
The present invention also provides nutritional compositions including proteins, fats, carbohydrates, and calcium salts;
the proteins include lactoferrin and osteopontin;
in the nutritional composition, the total protein content is (9-50 g)/100 g, the fat content is (12-30 g)/100 g, the carbohydrate content is (30-60 g)/100 g, the lactoferrin content is (0.005-3 g)/100 g, the osteopontin content is (0.01-1 g)/100 g, and the calcium content is (0.1-2 g)/100 g.
In the present invention, the nutritional composition specifically comprises 0 to 200 parts by weight of whey protein powder; 0-100 parts by weight of sodium caseinate; 0-100 parts by weight of casein; 0-400 parts by weight of solid corn syrup; 0-400 parts by weight of maltodextrin; 0-50 parts by weight of resistant dextrin; 0-50 parts by weight of fructo-oligosaccharide; 0-150 parts by weight of sunflower seed oil; corn oil 0-40 weight portions; 20-80 parts by weight of soybean oil; 0-100 parts by weight of medium chain triglyceride; 0-10 parts by weight of tryptophan; arginine 0-10 weight portions; 0.01 to 7.5 parts by weight of lactoferrin; 0.75 to 37.5 parts by weight of osteopontin; 0.0075-300 parts by weight of calcium salt; 7-50 parts by weight of compound nutrient packet containing calcium powder, vitamins and minerals; DHA 5-80 weight portions; 0-100 parts by weight of glutamine; EPA 10-140 weight portions.
The method for preparing the nutritional composition is not particularly limited, and conventional methods in the art may be employed. The preparation method of the nutritional composition comprises the following steps: proportioning, homogenizing, concentrating, sterilizing, spray drying and dry mixing to obtain a finished product;
the preparation method preferably comprises the following steps:
1) Powder adding: the powder raw materials are uniformly added into a powder preparation tank for storage through an air-assisted system after being metered according to the formula;
2) Vacuum powder suction: various powder raw materials in the powder preparation tank are sucked into the vacuum mixing tank through the vacuum system;
3) Melting and oil preparing: placing the grease specified in the formula into a grease melting room according to the formula requirement;
4) And (3) storing the mixed oil: the mixed oil is stored in an oil storage tank in a heat-preserving way;
5) Weighing: pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement;
6) Nutrient dissolution and addition: dissolving the compound nutrient package with water, and adding into a mixing tank;
7) Lactoferrin, osteopontin and calcium salt solubilization addition: dissolving osteopontin and calcium salt according to the step in the step 6, and adding the dissolved osteopontin and calcium salt into a mixing tank;
8) And (3) filtering: filtering the mixed feed liquid through a filter screen to remove physical impurities in the raw materials;
9) Homogenizing: homogenizing the filtered feed liquid by a homogenizer;
10 Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling;
11 Concentration sterilization: double-effect concentration is used during production; the discharge concentration is 48% -52% of dry matter;
12 Concentrated milk storage, pre-heating filtration, spray drying: temporarily storing the concentrated milk in a concentrated milk balance tank; preheating, filtering and drying the materials, and agglomerating the obtained fine powder at the top of the tower;
13 Fluidized bed drying and cooling: the powder from the drying tower is subjected to fluidized bed (first-stage) secondary drying and then is cooled by the fluidized bed (second-stage);
14 Split charging: weighing DHA, ARA and lactoferrin by powder workshop personnel according to the formula requirement, bagging and subpackaging;
15 Dry blending): mixing the weighed DHA, EPA, ARA, lactoferrin and milk powder uniformly in a dry mixer; if the protein content is higher, the protein can be added by uniformly mixing part of casein, whey protein powder and sodium caseinate in a dry mixing mode;
16 Screening powder: the granularity of the milk powder is uniform through a vibrating screen, and the powder slag is scrapped;
17 Powder discharge: receiving powder by a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room;
18 Powder) is added: pouring milk powder into a powder storage tank on a size packaging machine according to the packaging requirement;
19 Packaging: 800 g of automatic packaging machine fills nitrogen for packaging, and the oxygen content is lower than 1% during nitrogen filling; 900 g of iron cans automatically fill nitrogen and pack oxygen content lower than 5%;
20 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine;
21 Inspection of the finished product: sampling and checking the packaged product according to a checking plan;
22 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
The nutritional composition provided by the invention contains lactoferrin, osteopontin and calcium, has a synergistic inhibition effect on inflammation, particularly has a synergistic inhibition effect on chronic inflammation which is easy to generate in adult diseased states of tumor patients, trauma stress patients and the like, has high safety, and is worthy of popularization and application. The experimental examples prove that the three components of lactoferrin, osteopontin and calcium can relieve the expression of the RAW264.7 macrophage inhibiting the pro-inflammatory factor at the mRNA level under the induction of LPS under the limit proportion, and can down regulate the expression of the protein related to the inflammatory pathway at the protein level, thereby relieving the influence of inflammatory reaction.
Drawings
FIG. 1 is a flow chart of LF-OPN-calcium ion treatment of macrophages in an experimental example of the invention;
FIG. 2 shows the effect of LF-OPN-calcium combination on cells under LPS in experimental examples of the invention;
FIG. 3 shows the effect of lactoferrin, osteopontin undigested matter on cell activity in experimental examples of the present invention;
FIG. 4 shows the effect of lactoferrin and osteopontin digests on cell activity in experimental examples of the invention;
FIG. 5 is the effect of LF-OPN-calcium combination on IL-1β mRNA level expression in experimental examples of the invention;
FIG. 6 is the effect of LF-OPN-calcium combination on IL-6mRNA level expression in experimental examples of the invention;
FIG. 7 shows the effect of LF-OPN-calcium combinations on inflammatory pathway-related protein expression in experimental examples of the invention;
FIG. 8 is the effect of LF-OPN combination and LF-OPN-calcium combination on IL-1β mRNA level expression in experimental examples of the invention.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
In order to further illustrate the present invention, the following examples are provided. The raw materials used in the following examples of the present invention are all commercially available.
The nutritional composition content in the nutritional package of the present invention is as follows:
1) A compound vitamin nutrition package, wherein each gram of compound vitamin nutrition package comprises:
taurine: 140-340 mg
Vitamin a: 1700-5800 mu gRE
Vitamin D: 25-70 mu g
Vitamin B 1 ：2000～6800μg
Vitamin B 2 ：3000～6900μg
Vitamin B 6 ：1700～4000μg
Vitamin B 12 ：8～20μg
Vitamin K 1 ：200～700μg
Vitamin C: 0-700 mg
Vitamin E: 10-70 mg alpha-TE
Nicotinamide: 10000-41550 mug
Folic acid: 350-920 mu g
Biotin: 70-245 mug
Pantothenic acid: 7100-25230 mu g
Inositol: 0-250mg
L-carnitine: 0-60mg.
2) Mineral one nutrition package, in every gram of mineral one nutrition package:
iron: 20-110 mg
Zinc: 23-90 mg
Copper: 2000-4180 mug
Iodine: 500-995 mug
Selenium: 0-200 mu g
Manganese: 0-579 mug
3) Mineral two nutrition package, in every gram mineral two nutrition package:
sodium: 40-100 mg
Potassium: 200-500 mg
4) Mineral triad package, per gram of mineral triad package:
calcium: 200-500 mg
Phosphorus: 75-300 mg.
The calcium salt in the mineral tri-nutrition bag is calcium carbonate, calcium hydrogen phosphate and tricalcium phosphate.
Example 1 contains tumor patient formula (1000 kg prepared):
70kg of casein, 70kg of whey protein powder, 200kg of sodium caseinate, 320kg of maltodextrin, 60 kg of corn oil, 40 kg of soybean oil, 20kg of medium chain triglyceride, 30 kg of fructo-oligosaccharide, 6 kg of lactoferrin, 0.6 kg of osteopontin, 3kg of calcium salt, 1kg of glutamine, 20kg of compound nutrient package, 50 kg of DHA, 80 kg of EPA, 0.5kg of arginine, 0.5kg of tryptophan and the balance of maltodextrin.
Wherein each gram of the compound nutrient package comprises about 6.0 parts by weight of compound vitamin nutrient package, about 2.0 parts by weight of choline chloride nutrient package, about 10 parts by weight of mineral three-nutrient package, 20 parts by weight of mineral two-nutrient package, about 6 parts by weight of mineral one-nutrient package and about 7.0 parts by weight of compound magnesium chloride nutrient package, and the base material of each nutrient package is maltodextrin.
The specific preparation process of the formula powder containing lactoferrin, osteopontin and calcium salt comprises the following steps:
1) Powder adding: the powder base material is metered according to the formula and then uniformly added into a powder preparation tank for storage through an air-assisted system.
2) Vacuum powder suction: various powder raw materials in the powder preparation tank are sucked into the vacuum mixing tank through the vacuum system.
3) Melting and oil preparing: the oil and fat specified in the formula are put into an oil melting room according to the formula requirement, the temperature of the oil melting room is kept at 50-90 ℃, and after the oil is melted, the oil is pumped into a mixed oil storage tank according to the formula proportion requirement through an oil pump and a flowmeter.
4) And (3) storing the mixed oil: the mixed oil is stored in an oil storage tank in a heat preservation way at the temperature of 40-50 ℃ for less than 12 hours to prevent fat oxidation.
5) Weighing: and pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.
6) Nutrient dissolution and addition: the compound nutrient package comprising calcium powder, mineral substances and vitamins is dissolved by 100-200 kg of purified water respectively, and then is put into a wet mixing tank, and a tank and a pipeline are added after each 100kg of purified water is used for flushing.
7) Lactoferrin, osteopontin and calcium salt solubilization addition: lactoferrin, osteopontin and calcium salt are dissolved according to the step in step 6 and added into a mixing tank.
8) And (3) filtering: the mixed feed liquid is filtered by a filter screen to remove physical impurities possibly carried in the raw materials.
9) Homogenizing: homogenizing the filtered feed liquid by a homogenizer, wherein the primary pressure of homogenization is 105+/-5 bar, and the secondary pressure is 32+/-3 bar, so that fat globules in the feed liquid are dispersed into uniform fat globules.
10 Cooling and storing: the homogenized feed liquid enters a plate heat exchanger for cooling: cooling to below 20 ℃, temporarily storing in a pre-storing cylinder, entering the next working procedure within 6 hours, and starting the stirrer according to the set requirement.
11 Concentration sterilization: during production, double-effect concentration is used, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds. The discharge concentration is 48% -52% of dry matter.
12 Concentrated milk storage, pre-heating filtration, spray drying: the concentrated milk is temporarily stored in a concentrated milk balance tank. Preheating to 60-70 ℃ by a scraper preheater, filtering the preheated material by a filter with the aperture of 1mm, pumping the material into a drying tower by a high-pressure pump for spray drying, and agglomerating the fine powder on the top of the tower or a fluidized bed according to requirements. Air inlet temperature: 165-180 deg.c, exhaust temperature 75-90 deg.c, high pressure pump pressure 160-210 bar, and negative tower pressure-4 to-2 mbar.
13 Fluidized bed drying and cooling: the powder from the drying tower is dried again by the fluidized bed (first stage) and then cooled to 25-30 ℃ by the fluidized bed (second stage).
14 Split charging: and weighing DHA, ARA and lactoferrin by powder workshop personnel according to the formula requirement, bagging and subpackaging.
15 Dry blending): and mixing the weighed DHA, EPA, ARA, lactoferrin and milk powder uniformly in a dry mixer.
16 Screening powder: the granularity of the milk powder is uniform through the vibrating screen, and the powder slag is scrapped.
17 Powder discharge: and (3) receiving powder by using a sterilized powder collecting box, and conveying the powder from a powder outlet room to a powder feeding room.
18 Powder) is added: and pouring the milk powder into a powder storage tank on a size packaging machine according to the packaging requirement.
19 Packaging: 800 g automatic packaging machine fills nitrogen and packages, and the oxygen content is lower than 1% during nitrogen filling.
20 Boxing: packaging the packaged small bags into a paper box, adding a powder spoon at the same time, and sealing by a box sealing machine.
21 Inspection of the finished product: sampling and checking the packaged product according to a checking plan.
22 Warehousing and storing: the qualified products are stored in warehouse, and the storage is required at normal temperature, and the humidity is less than or equal to 65%.
In the product of this example, the total protein content was 34g/100g, the fat content was 12g/100g, the carbohydrate content was 32g/100g, the lactoferrin was 600mg/100g, the osteopontin was 60mg/100g, the calcium content was 300mg/100g, and the mass ratio of lactoferrin, osteopontin and calcium was 1:0.1:0.5.
example 2 wound stress patient formula (1000 kg prepared):
60 kg of sodium caseinate, 70kg of casein, 200kg of whey protein powder, 340 kg of maltodextrin, 120 kg of corn oil, 30 kg of soybean oil, 35 kg of medium chain triglyceride, 30 kg of fructo-oligosaccharide, 0.16 kg of lactoferrin, 0.8 kg of osteopontin, 6 kg of calcium salt, 1kg of glutamine, 25 kg of compound nutrient package, 30 kg of DHA, 60 kg of EPA, 1kg of arginine, 1kg of tryptophan and the balance of maltodextrin.
Wherein each gram of the compound nutrient package comprises about 6.0 parts by weight of compound vitamin nutrient package, about 2.0 parts by weight of choline chloride nutrient package, about 20 parts by weight of mineral three-nutrient package, 20 parts by weight of mineral two-nutrient package, about 6 parts by weight of mineral one-nutrient package and about 7.0 parts by weight of compound magnesium chloride nutrient package, and the base material of each nutrient package is maltodextrin.
The product preparation process is as in example 1.
In the product of this example, the total protein content was 33g/100g, the fat content was 18.5g/100g, the carbohydrate content was 34g/100g, the lactoferrin was 16mg/100g, the osteopontin was 80mg/100g, the calcium content was 640mg/100g, and the mass ratio of lactoferrin, osteopontin and calcium was 1:5:40.
experimental example
1. Materials and reagents
RAW264.7 macrophage, calcium chloride, LPS, lactoferrin, osteopontin, PBS buffer solution, porcine trypsin, porcine pepsin and DMEM medium (Gibco, 11995065), wherein the purity of the calcium chloride is more than or equal to 99%, the lactoferrin is from Hilmar1000, and the osteopontin is from
OPN-10。
2. In vitro digestion of LF-OPN-calcium
(1) An experimental group is set, and the raw materials comprise the following components in proportion:
a first group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:5:0.06;
second group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:1:0.02;
third group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:0.15:0.0115;
fourth group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:0.1:0.011;
fifth group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:3:0.04.
sixth group: consists of lactoferrin, osteopontin and calcium chloride, wherein the mass ratio of calcium in the lactoferrin, the osteopontin and the calcium chloride is 1:0.02:0.012.
seventh group: consists of lactoferrin and osteopontin, wherein the mass ratio of the lactoferrin to the osteopontin is 1:0.2.
(2) LF, OPN and calcium are dissolved in the in-vitro digestive system simulating gastric digestive juice and intestinal digestive juice according to the proportion in the step (1), and digested samples are sterilized by a 0.22 mu m filter membrane before acting on cells.
3. LF-OPN-calcium ion treated macrophages
Will be 2X 10 5 RAW264.7 cells per well were seeded into 6-well plates, 3 replicates per treatment group. The inoculated cells were placed in 5% CO at 37 ℃C 2 After 24h, the DMEM medium without serum and antibiotics containing LF and OPN, calcium ions (monomer or combination after in vitro digestion) was replaced for 6h. LPS was then added to the medium to a concentration of 1. Mu.g/ml for a treatment period of 2h to collect cellsRNA was taken and acted for 6h to collect cell extract proteins, and the test procedure is shown in FIG. 1.
4. Detection index
(1) Cell morphology
RAW264.7 cells were inoculated into 12-well cell culture plates, and after 24 hours, DMEM medium containing LF, OPN, calcium ions and no serum and antibiotics was changed. After 6h incubation of the protein, LPS was added to a concentration of 1. Mu.g/ml for 6h. And photographing RAW264.7 cells treated at different time points by using an inverted microscope, recording cell morphology, and characterizing the differentiation degree.
The experimental results are shown in fig. 2, and in fig. 2, left: blank control group; in (a): a LPS group; right: lactoferrin-osteopontin-calcium combination + LPS group. After LPS action for 6h, RAW264.7 changes the cell shape from round shape to slender shape when it is not differentiated; however, in the case of the advanced action of the active protein-calcium combination for 6 hours, the morphology of the cells after the action of LPS for 6 hours was somewhat closer to that of the cells when they were not differentiated than when LPS alone was added.
(2) Cell Activity
Cytotoxicity of the active protein against RAW264.7 was determined by CCK8 experiments. Cells were cultured in 96-well plates, treated for 12h with serum-and antibiotic-free DMEM medium containing LF-OPN-calcium digest, and treated for 1h with CCK 8-free DMEM medium containing no serum and antibiotic. Absorbance was measured with a microplate reader at a wavelength of 450 nm.
As shown in FIG. 3 and FIG. 4, when the concentrations of LF and OPN are higher than 5mg/ml, the effect on cell activity is large, and when the concentrations are lower than 1mg/ml, the cell toxicity is small, so that the monomer or mixed concentration of LF and OPN is 1mg/ml in the experiment.
(3) Expression of inflammatory factors
RAW264.7 cells were inoculated into 12-well cell culture plates and after 24h the DMEM medium containing LF-OPN-calcium and free of serum and antibiotics was changed. After 6h LPS was added to a concentration of 1. Mu.g/ml. RNA is collected after 2 hours, and the expression level of inflammatory factors such as IL-6, IL-1 beta and the like in mRNA is quantitatively analyzed by RT-qPCR.
IL-1 beta and IL-6 are the most common pro-inflammatory factors, and experimental results are shown in fig. 5 and 6, and it can be seen that the LF and OPN monomer digests can inhibit the expression of inflammatory factor genes, but the composition has a synergistic effect, and in the mixed digests, when the ratio is LF: OPN: ca=1: (0.1-5): (0.011-0.06) are superior to LF, OPN monomers and have statistical differences, as can be seen from fig. 8, lactoferrin, osteopontin and calcium group (LF: OPN: ca=1:0.2:0.012) have better anti-inflammatory effects and have statistical differences than the experimental group of lactoferrin and osteopontin (LF: opn=1:0.2).
(4) Inflammatory pathway-related protein expression
RAW264.7 cells were inoculated into 12-well cell culture plates, and after 24 hours, DMEM medium containing LF, OPN, calcium ions and no serum and antibiotics was changed. After 6h LPS was added to a concentration of 1. Mu.g/ml. And collecting protein samples after 6 hours, and analyzing the expression of TLR4 and NF- κB channel related proteins by Western blot.
After six hours of treatment of RAW264.7 with LPS, LF and OPN monomeric digests and different ratios of complex digests, expression of p-STAT3 in the membrane proteins TLR4, NF- κb pathway key protein p-p65 (p 65), and downstream JNK/STAT pathway was examined. The results are shown in fig. 7, and it can be seen that LF: OPN: ca=1: (0.1-5): (0.011-0.06), especially LF: OPN: ca=1: (0.1-5): the composition of (0.011-0.02) can inhibit the expression of inflammatory pathway protein better than the LF or OPN monomer.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (12)
1. Use of a nutritional composition for the preparation of an anti-inflammatory product;
the nutritional composition comprises protein, fat, carbohydrate and calcium salt;
the proteins include lactoferrin and osteopontin;
in the nutritional composition, the total protein content is (9-50 g)/100 g, the fat content is (12-30 g)/100 g, the carbohydrate content is (30-60 g)/100 g, the lactoferrin content is (0.005-3 g)/100 g, the osteopontin content is (0.01-1 g)/100 g, and the calcium content is (0.1-2 g)/100 g.
2. The use according to claim 1, wherein the mass ratio of lactoferrin, osteopontin and calcium is 1 (0.1-5): 0.001-40.
3. The use according to claim 1, wherein the anti-inflammatory product is a food product.
4. The use according to claim 3, wherein the anti-inflammatory product is a special medical use formula.
5. The use according to claim 1, wherein the anti-inflammatory is against chronic inflammation.
6. The use according to claim 5, wherein the patient suffering from the chronic inflammation is a tumor patient or a trauma stress patient.
7. The use according to claim 1, characterized in that in the nutritional composition the total protein content is (15-35 g)/100 g, the fat content is (12-20 g)/100 g, the carbohydrate content is (32-50 g)/100 g, the lactoferrin content is (0.005-0.8 g)/100 g, the osteopontin content is (0.03-0.5 g)/100 g, and the calcium content is (0.1-1 g)/100 g.
8. The use according to claim 1, wherein the lactoferrin is derived from one or more of cow's milk or a preparation thereof, sheep's milk or a preparation thereof, camel's milk or a preparation thereof;
the osteopontin is one or more from cow milk or a product thereof, sheep milk or a product thereof, camel milk or a product thereof;
the calcium salt is selected from one or more of calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, calcium hydrogen phosphate, L-threonine calcium, calcium glycine, calcium aspartate, calcium acetate, calcium chloride, tricalcium phosphate, calcium vitamin E succinate, calcium glycerophosphate, calcium sulfate, calcium dihydrogen phosphate, milk mineral salt, calcium caseinate, calcium malate, and calcium ascorbate.
9. The use according to claim 1, wherein the raw materials providing the protein comprise one or more of sodium caseinate, calcium caseinate, casein, hydrolysed whey protein, hydrolysed casein, hydrolysed milk protein, hydrolysed milk fat globule membrane protein, isolated whey protein;
the raw materials for providing the fat comprise one or more of milk fat, vegetable oil, fish oil and triglyceride.
10. The use according to any one of claims 1-9, wherein the nutritional composition further comprises one or more of amino acids, nucleotides, vitamins, probiotics, inorganic salts.
11. Nutritional composition characterized by comprising proteins, fats, carbohydrates and calcium salts;
the proteins include lactoferrin and osteopontin;
in the nutritional composition, the total protein content is (9-50 g)/100 g, the fat content is (12-30 g)/100 g, the carbohydrate content is (30-60 g)/100 g, the lactoferrin content is (0.005-3 g)/100 g, the osteopontin content is (0.01-1 g)/100 g, and the calcium content is (0.1-2 g)/100 g.
12. Nutritional composition according to claim 11, characterized in that it comprises in particular 0-200 parts by weight of whey protein powder; 0-100 parts by weight of sodium caseinate; 0-100 parts by weight of casein; 0-400 parts by weight of solid corn syrup; 0-400 parts by weight of maltodextrin; 0-50 parts by weight of resistant dextrin; 0-50 parts by weight of fructo-oligosaccharide; 0-150 parts by weight of sunflower seed oil; corn oil 0-40 weight portions; 20-80 parts by weight of soybean oil; 0-100 parts by weight of medium chain triglyceride; 0-10 parts by weight of tryptophan; arginine 0-10 weight portions; 0.01 to 7.5 parts by weight of lactoferrin; 0.75 to 37.5 parts by weight of osteopontin; 0.0075-300 parts by weight of calcium salt; 7-50 parts by weight of compound nutrient packet containing calcium powder, vitamins and minerals; DHA 5-80 weight portions; 0-100 parts by weight of glutamine; EPA 10-140 weight portions.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310273135.4A CN116172191B (en) | 2023-03-17 | 2023-03-17 | Nutritional composition and its application in preparing anti-inflammatory products |
| PCT/CN2023/135413 WO2024114729A1 (en) | 2022-11-30 | 2023-11-30 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310273135.4A CN116172191B (en) | 2023-03-17 | 2023-03-17 | Nutritional composition and its application in preparing anti-inflammatory products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116172191A true CN116172191A (en) | 2023-05-30 |
| CN116172191B CN116172191B (en) | 2024-08-06 |
Family
ID=86450698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310273135.4A Active CN116172191B (en) | 2022-11-30 | 2023-03-17 | Nutritional composition and its application in preparing anti-inflammatory products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116172191B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190388518A1 (en) * | 2017-12-01 | 2019-12-26 | ByHeart | Formulations for Nutritional Support in Subjects in Need Thereof |
| CN111990462A (en) * | 2020-08-18 | 2020-11-27 | 黑龙江省完达山乳业股份有限公司 | Infant formula containing protein composition and preparation method thereof |
| CN112075504A (en) * | 2020-09-30 | 2020-12-15 | 石家庄君乐宝乳业有限公司 | Infant formula milk powder for enhancing immunity |
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
-
2023
- 2023-03-17 CN CN202310273135.4A patent/CN116172191B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190388518A1 (en) * | 2017-12-01 | 2019-12-26 | ByHeart | Formulations for Nutritional Support in Subjects in Need Thereof |
| CN111990462A (en) * | 2020-08-18 | 2020-11-27 | 黑龙江省完达山乳业股份有限公司 | Infant formula containing protein composition and preparation method thereof |
| CN112075504A (en) * | 2020-09-30 | 2020-12-15 | 石家庄君乐宝乳业有限公司 | Infant formula milk powder for enhancing immunity |
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| LI, CA等: "Synergistic effect of lactoferrin and osteopontin on intestinal barrier injury", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, no. 253, 31 December 2023 (2023-12-31), pages 127416 * |
| LIU, L等: "Assessment of bioactivities of the human milk lactoferrin-osteopontin complex in vitro", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 69, 31 July 2019 (2019-07-31), pages 10 - 18, XP085709712, DOI: 10.1016/j.jnutbio.2019.03.016 * |
| 刘兰: "乳铁蛋白与骨桥蛋白互作及其复合物的生物活性功能研究", 中国博士学位论文全文数据库工程科技Ⅰ辑, no. 1, 15 January 2020 (2020-01-15), pages 024 - 49 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
| CN116076739B (en) * | 2022-11-30 | 2024-08-06 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116172191B (en) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2026791B2 (en) | Maternal supplement | |
| CN116172191B (en) | Nutritional composition and its application in preparing anti-inflammatory products | |
| EP1194138A1 (en) | Nutritional supplements | |
| JP2012197293A (en) | Total enteral nutritious composition | |
| CN105558046A (en) | Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof | |
| CN114568526A (en) | Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof | |
| CN105007761A (en) | Nutritional composition containing peptide component with adiponectin simulating properties and uses thereof | |
| CN107668211A (en) | A kind of infant formula goat milk powder for strengthening immunologic function and preparation method thereof | |
| CN116114767A (en) | Dairy products and their use in the preparation of anti-inflammatory products | |
| CN114208893B (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114128767B (en) | Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides | |
| CN110074189A (en) | A kind of infant's diatery supplement and preparation method thereof adding human milk oligosaccharides | |
| CN114145353A (en) | A formula milk powder that can improve the health of intestinal microenvironment and its preparation method and application | |
| FR2560013A1 (en) | FERMENTATION PRODUCT OF MILK | |
| CN113796419A (en) | A kind of formula sheep milk powder for improving immunity of children and preparation method thereof | |
| CN117598475A (en) | Total nutrient formula food for special medical use for adults and preparation method thereof | |
| CN107467193A (en) | Full nutrition special medicine purposes formula food of a kind of pulvis based on goat milk and preparation method thereof | |
| CN110584120A (en) | Bone health composition | |
| CN114145356B (en) | Formula milk powder capable of improving immune response and preparation method and application thereof | |
| WO2024114729A1 (en) | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof | |
| CN115669732B (en) | Hypoallergenic infant partially hydrolyzed formula containing the breast milk oligosaccharide LNnT | |
| CN108902933A (en) | Prostate cancer wholefood and preparation method thereof | |
| CN119074901A (en) | Albumin peptide composition for improving hypoproteinemia, preparation method and application thereof | |
| CN117617313A (en) | A special medical infant food containing DHA easy to digest and absorb | |
| CN117481215A (en) | Special medical infant food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |